{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:13:55Z","timestamp":1784052835494,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Commercialization Promotion Agency for R&D Outcomes(COMPA) - Grant funded by the Ministry of Science and IC","award":["RS-2026-25532483"],"award-info":[{"award-number":["RS-2026-25532483"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00520-026-10895-5","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:59:59Z","timestamp":1781661599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical vulnerability to chemotherapy in cholangiocarcinoma: impact of nutritional status, frailty, and systemic inflammation"],"prefix":"10.1007","volume":"34","author":[{"given":"Ho Seung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Jo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Soon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Keum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Tae","family":"Jeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"1","key":"10895_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10895_CR2","doi-asserted-by":"publisher","first-page":"10206","DOI":"10.1038\/s41598-022-13605-3","volume":"12","author":"MJ Kang","year":"2022","unstructured":"Kang MJ et al (2022) Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 12(1):10206. https:\/\/doi.org\/10.1038\/s41598-022-13605-3","journal-title":"Sci Rep"},{"key":"10895_CR3","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.09.10","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Sendilnathan A, Siddiqi NI, Gulati S, Ghose A, Xie C, Olowokure OO (2016) Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol. https:\/\/doi.org\/10.21037\/jgo.2016.09.10","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"10895_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evidence"},{"key":"10895_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101170","volume":"50","author":"L Rimassa","year":"2025","unstructured":"Rimassa L et al (2025) New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe. Lancet Reg Health Eur 50:101170. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101170","journal-title":"Lancet Reg Health Eur"},{"issue":"14","key":"10895_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"8","key":"10895_CR7","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.3390\/curroncol30080524","volume":"30","author":"T Okamoto","year":"2023","unstructured":"Okamoto T et al (2023) Safety and effectiveness of chemotherapy in elderly biliary tract cancer patients. Curr Oncol 30(8):7229\u20137240. https:\/\/doi.org\/10.3390\/curroncol30080524","journal-title":"Curr Oncol"},{"key":"10895_CR8","doi-asserted-by":"publisher","first-page":"175883592513440","DOI":"10.1177\/17588359251344013","volume":"17","author":"M Valery","year":"2025","unstructured":"Valery M et al (2025) Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi). Ther Adv Med Oncol 17:17588359251344012. https:\/\/doi.org\/10.1177\/17588359251344013","journal-title":"Ther Adv Med Oncol"},{"issue":"10391","key":"10895_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"issue":"8","key":"10895_CR10","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S, Mertens C, Delva F, Fonck M, Soubeyran PL (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166\u20132172. https:\/\/doi.org\/10.1093\/annonc\/mdr587","journal-title":"Ann Oncol"},{"key":"10895_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tipsro.2020.09.001","volume":"16","author":"A O\u2019Donovan","year":"2020","unstructured":"O\u2019Donovan A, Leech M (2020) Personalised treatment for older adults with cancer: the role of frailty assessment. Tech Innov Patient Support Radiat Oncol 16:30\u201338. https:\/\/doi.org\/10.1016\/j.tipsro.2020.09.001","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"12","key":"10895_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115060","volume":"9","author":"P Soubeyran","year":"2014","unstructured":"Soubeyran P et al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE 9(12):e115060. https:\/\/doi.org\/10.1371\/journal.pone.0115060","journal-title":"PLoS ONE"},{"issue":"3 Pt A","key":"10895_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ejso.2020.03.202","volume":"47","author":"MG McNamara","year":"2021","unstructured":"McNamara MG, de Liguori Carino N, Kapacee ZA, Lamarca A, Valle JW (2021) Outcomes in older patients with biliary tract cancer. Eur J Surg Oncol 47(3 Pt A):569\u2013575. https:\/\/doi.org\/10.1016\/j.ejso.2020.03.202","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10895_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ags3.12601","volume":"7","author":"K Mima","year":"2023","unstructured":"Mima K, Nakagawa S, Miyata T, Yamashita YI, Baba H (2023) Frailty and surgical outcomes in gastrointestinal cancer: integration of geriatric assessment and prehabilitation into surgical practice for vulnerable patients. Ann Gastroenterol Surg 7(1):27\u201341. https:\/\/doi.org\/10.1002\/ags3.12601","journal-title":"Ann Gastroenterol Surg"},{"issue":"10","key":"10895_CR15","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1007\/s00464-024-11103-3","volume":"38","author":"A Tran","year":"2024","unstructured":"Tran A, Putnam LR, Lipham JC, Shiraga S (2024) Utility of the mFI-5 as a predictor of post-operative outcomes following gastrectomy for gastric cancer: an ACS-NSQIP analysis. Surg Endosc 38(10):5922\u20135928. https:\/\/doi.org\/10.1007\/s00464-024-11103-3","journal-title":"Surg Endosc"},{"issue":"11","key":"10895_CR16","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.ejso.2015.07.022","volume":"41","author":"Y Geng","year":"2015","unstructured":"Geng Y, Qi Q, Sun M, Chen H, Wang P, Chen Z (2015) Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol 41(11):1508\u20131514. https:\/\/doi.org\/10.1016\/j.ejso.2015.07.022","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10895_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4251\/wjgo.v8.i7.555","volume":"8","author":"JM Lee","year":"2016","unstructured":"Lee JM et al (2016) Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 8(7):555\u2013562. https:\/\/doi.org\/10.4251\/wjgo.v8.i7.555","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"10895_CR18","doi-asserted-by":"publisher","first-page":"23678","DOI":"10.1038\/s41598-024-75252-0","volume":"14","author":"G-P Li","year":"2024","unstructured":"Li G-P et al (2024) Association between the neutrophil-to-lymphocyte ratio and cancer in adults from NHANES 2005\u20132018: a cross-sectional study. Sci Rep 14(1):23678. https:\/\/doi.org\/10.1038\/s41598-024-75252-0","journal-title":"Sci Rep"},{"issue":"5","key":"10895_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/his.15125","volume":"84","author":"JJX Li","year":"2024","unstructured":"Li JJX et al (2024) Neutrophil\u2013lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy. Histopathology 84(5):810\u2013821. https:\/\/doi.org\/10.1111\/his.15125","journal-title":"Histopathology"},{"issue":"1","key":"10895_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s00423-024-03483-w","volume":"409","author":"A Khalid","year":"2024","unstructured":"Khalid A et al (2024) Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Langenbecks Arch Surg 409(1):286. https:\/\/doi.org\/10.1007\/s00423-024-03483-w","journal-title":"Langenbecks Arch Surg"},{"issue":"6","key":"10895_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.21873\/cdp.10388","volume":"4","author":"S Okada","year":"2024","unstructured":"Okada S et al (2024) Five-item modified frailty index in elderly patients undergoing laparoscopic colorectal surgery predicts postoperative complications. Cancer Diagn Progn 4(6):729\u2013734. https:\/\/doi.org\/10.21873\/cdp.10388","journal-title":"Cancer Diagn Progn"},{"issue":"19","key":"10895_CR22","doi-asserted-by":"publisher","first-page":"32171","DOI":"10.18632\/oncotarget.16291","volume":"8","author":"RC Bowen","year":"2017","unstructured":"Bowen RC et al (2017) Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget 8(19):32171\u201332189. https:\/\/doi.org\/10.18632\/oncotarget.16291","journal-title":"Oncotarget"},{"issue":"9","key":"10895_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG et al (2014) Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 50(9):1581\u20131589. https:\/\/doi.org\/10.1016\/j.ejca.2014.02.015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10895_CR24","doi-asserted-by":"publisher","first-page":"12691","DOI":"10.1038\/s41598-022-16727-w","volume":"12","author":"D Liu","year":"2022","unstructured":"Liu D et al (2022) The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis. Sci Rep 12(1):12691. https:\/\/doi.org\/10.1038\/s41598-022-16727-w","journal-title":"Sci Rep"},{"issue":"10","key":"10895_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.hpb.2020.02.002","volume":"22","author":"M Mady","year":"2020","unstructured":"Mady M et al (2020) Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. HPB (Oxford) 22(10):1490\u20131495. https:\/\/doi.org\/10.1016\/j.hpb.2020.02.002","journal-title":"HPB (Oxford)"},{"issue":"4","key":"10895_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469\u2013474. https:\/\/doi.org\/10.1038\/sj.bjc.6605779","journal-title":"Br J Cancer"},{"issue":"1","key":"10895_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3967-0","volume":"18","author":"AR Siebenh\u00fcner","year":"2018","unstructured":"Siebenh\u00fcner AR et al (2018) Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer 18(1):72. https:\/\/doi.org\/10.1186\/s12885-017-3967-0","journal-title":"BMC Cancer"},{"issue":"1","key":"10895_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas. Actas Dermo-Sifiliogr 112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"3","key":"10895_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5946\/ce.2024.155","volume":"58","author":"S Peppas","year":"2025","unstructured":"Peppas S, Suvarnakar A, Abujaber BA, Altork N, Arman A, Alzraikat S et al (2025) Endoscopic ultrasound-guided biliary drainage versus endoscopic retrograde cholangiopancreatography biliary drainage in the palliative management of malignant distal biliary obstruction: an updated systematic review and meta-analysis of randomized controlled trials. Clin Endosc 58(3):386\u2013397. https:\/\/doi.org\/10.5946\/ce.2024.155","journal-title":"Clin Endosc"},{"issue":"3","key":"10895_CR30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/liv.14314","volume":"40","author":"M Salati","year":"2020","unstructured":"Salati M et al (2020) The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver Int 40(3):704\u2013711. https:\/\/doi.org\/10.1111\/liv.14314","journal-title":"Liver Int"},{"issue":"7","key":"10895_CR31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65003","volume":"16","author":"O\u0130 Delikta\u015f","year":"2024","unstructured":"Delikta\u015f O\u0130 et al (2024) Is the prognostic nutritional index a novel prognostic factor in patients with unresectable\/metastatic gallbladder and cholangiocarcinoma receiving chemotherapy? Cureus 16(7):e65003. https:\/\/doi.org\/10.7759\/cureus.65003","journal-title":"Cureus"},{"key":"10895_CR32","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.2147\/OTT.S112501","volume":"9","author":"C Zhang","year":"2016","unstructured":"Zhang C et al (2016) Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma. Onco Targets Ther 9:6417\u20136423. https:\/\/doi.org\/10.2147\/OTT.S112501","journal-title":"Onco Targets Ther"},{"issue":"22","key":"10895_CR33","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG et al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36(22):2326\u20132347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687","journal-title":"J Clin Oncol"},{"issue":"8","key":"10895_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2025.100743","volume":"6","author":"C Kenis","year":"2025","unstructured":"Kenis C et al (2025) Effectiveness of comprehensive geriatric assessment with extensive patient coaching for improving quality of life in older patients with solid tumours receiving systemic therapy (G-oncoCOACH): a multicentre randomised controlled trial. Lancet Healthy Longev 6(8):100743. https:\/\/doi.org\/10.1016\/j.lanhl.2025.100743","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"10895_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.critrevonc.2010.01.003","volume":"77","author":"T Aparicio","year":"2011","unstructured":"Aparicio T, Girard L, Bouarioua N, Patry C, Legrain S, Soul\u00e9 JC (2011) A mini geriatric assessment helps treatment decision in elderly patients with digestive cancer. A pilot study. Crit Rev Oncol Hematol 77(1):63\u201369. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.01.003","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10895-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10895-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10895-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:03Z","timestamp":1784052183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10895-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10895"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10895-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Korea University Anam Hospital, Korea (Approval No.: 2025AN0462; approval date: September 25, 2025). Informed consent was waived due to the study\u2019s retrospective design. Study registration and animal experiments were not applicable.","order":1,"name":"Ethics","label":"Ethics\u00a0Statements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"665"}}